CureMatch Selected to Join Inaugural Dubai Future Accelerators Program
Dubai, United Arab Emirates, September 19, 2016 – CureMatch, Inc., a San Diego-based digital health company, was accepted into the inaugural Dubai Future Accelerators program.
CureMatch is transforming the standard of care in oncology. The CureMatch proprietary decision support system guides oncologists in the selection of drug combinations for improved cancer therapy. A team from CureMatch will be working in Dubai with the Dubai Health Authority during the 12 week program to setup strategic partnerships with local health care institutions and to implement precision medicine solutions tailored for regional needs. The goals are to significantly improve cancer treatment in the United Arab Emirates and to transform Dubai into a global epicenter for precision medicine.
Dubai Future Accelerators is the largest government-supported accelerator that connects the world’s most innovative companies, entrepreneurs, and businesses with leading government departments to create transformational solutions with a global impact. Backed by a 1 Billion AED fund (USD $275M), the uniqueness of this program lies in its drive to not only visualize innovative ideas, but to see them become a reality with an impact regionally and globally. Only 30 companies were accepted into the program out of 2274 applicants from 73 countries. CureMatch is one of only five companies selected from the healthcare space.
“We are very honored and excited to have been selected to participate in this prestigious program,” said Stephane Richard, Ph.D., CEO of CureMatch. “This is a unique opportunity for us to expand the diversity of our patient database while also learning how care is provided, how data is managed, and what the specific needs are for oncologists and cancer patients in this region.”
“By implementing our decision support platform in local hospitals, we will be able to virtually transfer knowledge from our world-class clinical partners, such as oncologists from the UCSD Moore’s Cancer Center, directly to hospitals in the region,” added Martin Culjat, Ph.D., VP of Product at CureMatch. “We expect this pilot to be the first step in the global deployment of our product.”
CureMatch™, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch’s Decision Support System guides oncologists in the selection of cancer drugs that are customized for individual patients based on their molecular tumor profile. CureMatch enables oncologists to become experts in personalized medicine by providing them with actionable intelligence towards advanced cancer treatment options. For more information visit www.curematch.com.